1st April marks the start of the annual Parkinson’s Awareness Month. This year, we will focus on some of the positive advances in the treatment of Parkinson’s disease (PD). This progressive neurological condition affects movement and quality of life for millions of people worldwide. Current therapies, including dopamine receptor-targeting medications, remain effective for managing symptoms, and most patients continue to do well on established treatments. Research is moving quickly, however, and several promising new approaches are now in clinical trials. This article reviews what those developments mean for people already living with PD and the families who support them.
Understanding Parkinson’s disease and current treatment
PD develops when neurons in a brain region called the substantia nigra begin to degenerate. These neurons produce dopamine, a chemical messenger that coordinates movement and muscle control. As dopamine levels fall, symptoms emerge.
The main symptoms include:
- Resting tremors, typically beginning in one hand.
- Slowness of movement, known as bradykinesia.
- Muscle stiffness and rigidity in the limbs and trunk.
- Balance problems and a heightened risk of falls.
Non-motor symptoms such as sleep disruption, mood changes, and cognitive difficulties can also develop over time and have a significant impact on daily life. PD is incurable, but medication manages symptoms effectively for most patients, often for many years.
How dopamine receptor therapies work in PD
Most current PD medications work by supporting the dopamine system through one of four routes: replacing dopamine that has been used up, slowing its breakdown, sensitizing dopamine receptors to the dopamine that remains, or stimulating dopamine release directly. Each drug class takes a different approach to this goal.
Levodopa-based therapies are the most widely used. Levodopa (L-DOPA) is a precursor to dopamine. The brain converts it into dopamine once it crosses the blood-brain barrier. Because most levodopa breaks down before it reaches the brain, it is always combined with a second agent (carbidopa) that prevents premature breakdown. Stalevo adds a third component: entacapone, a COMT inhibitor that extends the life of each dose and reduces end-of-dose “wearing off.” Sinemet CR is a sustained-release formulation that provides a steadier supply of levodopa throughout the day.
Dopamine agonists work differently. Rather than raising dopamine levels, they activate the same receptors that dopamine normally targets. Mirapexin and Requip are prescribed both as early monotherapies and alongside levodopa in more advanced PD. Neupro is a transdermal patch used when oral medication is not suitable. Amandin is used in early-stage disease and as add-on therapy in later stages.
MAO-B inhibitors such as Azilect work by blocking the enzyme that breaks down free dopamine molecules, leaving more available to act on neurons. Azilect is often prescribed in early PD and may help delay the need to start levodopa.
As with all neurological medications, treatment plans should always be developed and monitored by a qualified healthcare provider. Adjustments to dosing or therapy class require medical input.
Five new dopamine receptors and neuroprotective strategies in the pipeline 
Research into disease-modifying therapies – treatments that slow or stop the underlying neurodegeneration, rather than just managing symptoms – has accelerated substantially. Several compounds are now progressing through clinical trials. Patients and caregivers should note that these are experimental treatments and are not yet approved for general use. Any decision to seek trial participation must be made with a neurologist.
1. Ambroxol: improving cellular cleanup: This repurposed cough suppressant acts as a molecular chaperone that boosts the activity of an enzyme in the brain’s lysosomes. Lysosomes are the cell’s waste-disposal system. When they function poorly, abnormal proteins that may accumulate in PD build up and cause damage. The GREAT trial in Europe is currently evaluating whether high-dose ambroxol slows motor progression in early-stage PD, particularly in patients carrying a GBA gene mutation. Earlier work has confirmed that ambroxol reaches the brain and raises GCase activity safely at therapeutic doses.
2. NLRP3 inflammasome inhibitors: targeting brain inflammation: Chronic low-grade inflammation in the brain is increasingly recognized as a driver of PD progression. A protein complex called the NLRP3 inflammasome, when persistently activated in brain immune cells, accelerates the accumulation of abnormal proteins and neuron death. Multiple compounds targeting this pathway are now in Phase 1 and Phase 2 trials. One agent has already completed a combined Phase 1b/2a trial in PD patients and showed reductions in neuroinflammatory markers.
3. AAV2-GDNF: gene therapy to protect neurons: This approach uses a harmless viral carrier to deliver a gene for a growth-supporting protein directly into the putamen area of the brain. GDNF promotes the survival and function of the dopaminergic neurons damaged by PD. A Phase 2 trial is currently under way to assess safety and early efficacy of this approach in patients with moderately advanced disease.
4. Solangepras (CVN-424): a non-dopaminergic motor pathway: This oral compound works on a receptor called GPR6, which is concentrated in the brain region most involved in motor control. By modulating this pathway without touching the dopamine system directly, solangepras may improve motor and cognitive function while reducing the side effects associated with dopaminergic drugs. A Phase 2 trial found that the 150 mg dose reduced daily “off” time, periods when levodopa is not working well. A Phase 3 trial is now underway.
5. Glovadalen (UCB0022) — enhancing the dopamine D1 receptor response: Rather than adding more dopamine or mimicking it directly, glovadalen amplifies the receptor’s response to whatever dopamine is already present. This fine-tuning approach may restore motor function with fewer of the side effects associated with stronger dopaminergic stimulation. A Phase 2 trial in advanced PD patients has recently been completed.
Comparison of current and emerging Parkinson’s disease treatments
| Treatment | How it works | Pros | Cons | Typical use |
|---|---|---|---|---|
| Stalevo | Boosts brain dopamine; extends levodopa action via COMT inhibition | Reduces wearing-off; single tablet convenience | Dyskinesia risk at higher doses | Moderate to advanced PD with motor fluctuations |
| Sinemet CR | Sustained-release dopamine precursor with carbidopa | Steadier dopamine levels; reduces dosing frequency | Absorption can be variable | Ongoing PD symptom management |
| Mirapexin | Dopamine agonist — activates dopamine receptors directly | Can be used as monotherapy or add-on; treats RLS | Impulse control side effects possible | Early to advanced PD |
| Neupro | Transdermal dopamine agonist | Continuous delivery; suitable when oral route is not | Skin reactions; patch management | When oral medication is not tolerated |
| Amandin | Dopamine release stimulant; also NMDA antagonist | Reduces dyskinesia; useful in early and late PD | Limited efficacy as sole therapy | Early PD or add-on in later stages |
| Requip | Dopamine agonist | Monotherapy option; delays need for levodopa | Nausea, sleepiness in early use | Early PD or alongside levodopa |
| Azilect | MAO-B inhibitor — prevents dopamine breakdown | Well tolerated; may delay need for levodopa | Dietary interactions possible | Early PD; add-on in later stages |
| Solangepras (investigational) | GPR6 inverse agonist — non-dopaminergic pathway | Reduces off-time without dopamine side effects | Not yet approved; trial data only | Phase 3 clinical trial |
| Ambroxol (investigational) | Lysosomal GCase enhancer — clears protein aggregates | Potential disease-modifying effect | Not yet approved; trial data only | Phase 2 clinical trial |
How to access Parkinson’s disease treatment advancements through IsraelPharm
For patients already managing PD with established medications, IsraelPharm is a reliable source for the branded products they rely on. IsraelPharm is a licensed international pharmacy operating under regulatory oversight. A valid prescription from a licensed physician is required for all prescription medications. Using an international pharmacy for supply does not change or replace the role of the prescribing physician.
Patients sourcing Stalevo, Sinemet CR, Mirapexin, Neupro, Amandin, Requip, or Azilect through IsraelPharm benefit from reliable supply continuity. For a condition like PD, where consistent, uninterrupted dosing matters greatly, knowing that the branded product is in stock and can be delivered directly to the home removes a practical burden. IsraelPharm stocks the exact branded medications prescribed, not substitutes, and the ordering process is straightforward to repeat.
Patients who want to stay informed about new developments in PD treatment, including emerging therapies in clinical trials, can rely on us as a trustworthy source of current, evidence-based information alongside medication supply. For more information about the medications listed here, visit the IsraelPharm website.
Frequently asked questions about Parkinson’s disease treatment advancements
What is the current standard of care for managing dopamine receptor decline in Parkinson’s disease?
The most widely used therapies work by supporting the brain’s dopamine system. Key approaches include:
- Levodopa combined with carbidopa (as in Sinemet CR or Stalevo) to boost dopamine levels in the brain.
- Dopamine agonists such as Mirapexin and Requip, which activate dopamine receptors directly.
- MAO-B inhibitors such as Azilect, which slow the breakdown of free dopamine.
Treatment is tailored to the individual. Physician oversight is essential for managing dosing and side effects.
Will new treatments replace existing PD medications like Stalevo or Azilect?
The new compounds in clinical trials are designed to complement, not replace, established therapies. Most target different mechanisms – inflammation, protein clearance, or non-dopaminergic pathways. Drugs like Stalevo and Azilect remain effective and widely prescribed. Any shift in therapy should only happen under medical guidance.
What does “disease-modifying” mean in the context of Parkinson’s disease treatment advancements?
Disease-modifying means the treatment aims to slow or stop the underlying neurodegeneration, not just relieve symptoms. Current medications manage symptoms effectively but do not halt disease progression. Therapies like ambroxol and AAV2-GDNF are being studied for their potential to change the course of PD rather than just ease its effects. None are approved for this purpose yet.
Is it safe to continue current PD medication while new treatments are being developed?
Yes. Established medications such as Neupro, Mirapexin, Requip, Stalevo, and Azilect have well-documented safety profiles. Patients should continue their prescribed regimen and discuss any new clinical trial information with their neurologist before considering changes. Stopping or reducing medication without medical advice is not recommended.
How can a patient access current PD medications reliably in the US?
Patients sourcing medications such as Stalevo, Sinemet CR, Mirapexin, or Azilect through IsraelPharm receive the exact branded product prescribed, delivered directly to their home. IsraelPharm is a licensed international pharmacy — a valid prescription is required. Supply is consistent, and the ordering process is designed to support ongoing treatment without gaps.
Glossary
- Dopamine — a neurotransmitter produced in the brain that plays a key role in controlling movement and coordination.
- Dopamine receptor — a protein on the surface of neurons that dopamine binds to in order to transmit signals that control movement.
- Substantia nigra — a small region of the brain where dopamine-producing neurons are concentrated and where degeneration in PD begins.
- Levodopa (L-DOPA) — a chemical precursor that the brain converts into dopamine; the most widely used treatment component in PD.
- Carbidopa — an agent combined with levodopa that prevents its breakdown before it reaches the brain, reducing side effects.
- COMT inhibitor — a drug that blocks the enzyme that breaks down levodopa, extending the duration of each dose’s effect.
- MAO-B inhibitor — a drug that blocks the enzyme responsible for degrading free dopamine molecules in the brain.
- Dopamine agonist — a drug that mimics dopamine by directly stimulating dopamine receptors, without needing dopamine conversion.
- Alpha-synuclein — a protein that forms abnormal clumps in the brains of people with PD, contributing to neuron damage.
- Lysosome — a compartment inside cells responsible for breaking down and clearing waste material, including damaged proteins.
- NLRP3 inflammasome — a protein complex in immune cells that, when chronically activated, drives inflammatory processes linked to neurodegeneration.
- Bradykinesia — the medical term for slowness of movement, one of the primary motor symptoms of PD.
- Allosteric modulator — a compound that enhances or reduces a receptor’s response to its natural activator without replacing it.
